Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, Ian Kremer, executive director of the leaders Engaged on Alzheimer's Disease (LEAD) coalition, spoke about several relevant topics regarding Alzheimer care as new novel therapeutics emerge. He talked about the lessons learned from the recent discontinuation of aducanumab, and the potential and limitations lecanemab (Leqembi; Eisai) and donanemab (Eli Lilly) may bring. Additionally, he provided comments about what matters to patients, the perception of the FDA approval process, and what is considered "clinically meaningful." Furthermore, he gave perspective on ways to improve drug development and emphasized the need for policy decisions to be based on scientific evidence and not by sensationalized headlines. Looking for more Alzheimer disease/dementia discussion? Check out the NeurologyLive® Alzheimer disease/dementia clinical focus page. Episode Breakdown: 1:10 – Promise in the Alzheimer field in 2024 4:05 – Ways of improving efficiencies with drug develpment 9:10 – Discontinuation of aducanumab 11:10– Neurology News Minute 13:50 – Lessons learned from aducanumab, antiamyloid therapies  22:10– Conversations between clinicians and patients surrounding expectations/limitations of antiamyloid therapies and available treatments The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: FDA Agrees to New Specialized Protocol for Phase 3b Study of ALS Agent NurOwn FDA Approves Alternate Administration Routes for Antiseizure Medication Cenobamate Extended Use of Investigational Agent IPX203 Safe in Parkinson Disease Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.